Novo Nordisk A/S
NOVO-B#110 of 134 by buybacksCO · Healthcare · Drug Manufacturers - General · Denmark
novonordisk.comBuybacks · TTM to Jun 2026DKK 5.90B≈ $884M · reported in DKK
Buyback yield0.5%repurchases ÷ market cap
Dividends · TTM to Jun 2026DKK 52.0Bdividend yield 4.6%
Shareholder yield5.1%buybacks + dividends ÷ market cap
Shares outstanding · 5 yr−3.2%4.44B shares (2026)
Buybacks ÷ free cash flow12%payout incl. dividends 118%
Fiscal-year detail
From the cash-flow statement as reported, in DKK. Negative repurchases mean net share issuance.
| Fiscal year | Repurchases | Dividends | Free cash flow |
|---|---|---|---|
| FY2025Dec 2025 | DKK 1.39B | DKK 51.8B | DKK 29.0B |
| FY2024Dec 2024 | DKK 20.2B | DKK 44.1B | DKK 69.7B |
| FY2023Dec 2023 | DKK 29.9B | DKK 31.8B | DKK 70.0B |
| FY2022Dec 2022 | DKK 24.1B | DKK 25.3B | DKK 64.1B |
| FY2021Dec 2021 | DKK 19.4B | DKK 21.5B | DKK 47.6B |
| FY2020Dec 2020 | DKK 16.9B | DKK 20.1B | DKK 29.9B |
| FY2019Dec 2019 | DKK 15.3B | DKK 19.4B | DKK 35.6B |
Repurchases in FY2025 were −93.1% versus the prior year.
About Novo Nordisk A/S
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides…
- Market cap
- DKK 1.13T
- P/E (trailing)
- 9.7×
- Fiscal year end
- December
- ISIN
- DK0062498333
- Reporting currency
- DKK
- Data updated
- Oct 10, 2026